$1700 | SAVE $300 | Single User
$3400 | SAVE $600 | Site License
$5100 | SAVE $900 | Enterprise License

Streptococcal Pneumonia - Pipeline Review, H2 2016
[Published by Global Markets Direct]

Published by Global Markets Direct: 21 Dec 2016 | 34725 | In Stock
Related Topics: Healthcare , Infectious Disease , Pneumonia

Introduction

Streptococcal Pneumonia - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Streptococcal Pneumonia – Pipeline Review, H2 2016, provides an overview of the Streptococcal Pneumonia (Infectious Disease) pipeline landscape.

Pneumococcal infections are caused by the Streptococcus pneumoniae (S. pneumoniae) bacterium. They can be mild or severe. Symptoms include fever, chills, sweat, aches and pains. Risk factors include serious health condition, such as HIV or diabetes that weakens their immune system, taking medication that weakens their immune system, such as chemotherapy and age. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Streptococcal Pneumonia – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Streptococcal Pneumonia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Streptococcal Pneumonia (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Streptococcal Pneumonia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 3, 6, 6, 2, 22, 10 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical and Discovery stages comprises 1, 1, 8 and 4 molecules, respectively.

Streptococcal Pneumonia (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Streptococcal Pneumonia (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Streptococcal Pneumonia (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Streptococcal Pneumonia (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Streptococcal Pneumonia (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Streptococcal Pneumonia (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Streptococcal Pneumonia (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Streptococcal Pneumonia (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
for Streptococcal Pneumonia - Pipeline Review, H2 2016 [Published by Global Markets Direct]

  • Table of Contents

    Table of Contents 2

    Introduction 5

    Streptococcal Pneumonia Overview 6

    Therapeutics Development 7

    Streptococcal Pneumonia - Therapeutics under Development by Companies 9

    Streptococcal Pneumonia - Therapeutics under Investigation by Universities/Institutes 11

    Streptococcal Pneumonia - Pipeline Products Glance 12

    Streptococcal Pneumonia - Products under Development by Companies 16

    Streptococcal Pneumonia - Products under Investigation by Universities/Institutes 19

    Streptococcal Pneumonia - Companies Involved in Therapeutics Development 20

    Streptococcal Pneumonia - Therapeutics Assessment 54

    Drug Profiles 64

    Streptococcal Pneumonia - Dormant Projects 136

    Streptococcal Pneumonia - Discontinued Products 140

    Streptococcal Pneumonia - Product Development Milestones 141

    Appendix 152

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

34725 | GMDHC8822IDB

Number of Pages

160

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 15% today! Group A Streptococcal Infection- Market Insights, Epidemiology and Market Forecast 2028
Report Summary"Group A Streptococcal Infection- Market Insights, Epidemiology and Market Forecast 20...
26 Jul 2019 by MIReports USD $5,083 (normally
USD $5,980)
More Info
SAVE 15% today! Group B Streptococcal Infection- Market Insights, Epidemiology and Market Forecast 2028
Report Summary"Group B Streptococcal Infection- Market Insights, Epidemiology and Market Forecast 20...
26 Jul 2019 by MIReports USD $5,083 (normally
USD $5,980)
More Info
SAVE 15% today! 2019 Streptococcal Infections Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025
The global clinical trial report- “2019 Streptococcal Infections Clinical Trials Study” provides com...
24 Apr 2019 by VPA Research USD $1,529 (normally
USD $1,799)
More Info
SAVE 15% today! Streptococcal Infections Global Clinical Trials Review, H2, 2018
Streptococcal Infections Global Clinical Trials Review, H2, 2018SummaryGlobalData's clinical trial r...
31 Aug 2018 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Streptococcal Infections-API Insights, 2017
The active pharmaceutical ingredients worldwide market is in continuous development from the recent ...
30 May 2017 by Delve Insight USD $1,063 (normally
USD $1,251)
More Info
SAVE 15% today! Streptococcal Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
DelveInsight’s Report, “Streptococcal Infections-Global API Manufacturers, Marketed and Phase III Dr...
30 May 2017 by Delve Insight USD $1,700 (normally
USD $2,000)
More Info
SAVE 15% today! Ampicillin Market Analysis: by Applications (Respiratory Tract Infection, Urinary Tract Infection, Meningitis, Salmonella Infections, Endocarditis, Others (Group 3 Streptococcal Infection, etc.)) Intake Method (by Mouth, by Injection into a Muscle, Intravenously) Target Bacteria Type (Gram Positive Bacteria, Gram Negative Bacteria)-Forecast(2016-2021)
Ampicillin, a semi-synthetic derivative of penicillin, causes cell death by interfering directly wit...
25 Jan 2016 by USD $4,463 (normally
USD $5,251)
More Info
SAVE 15% today! Streptococcal Infections Global Clinical Trials Review, H2, 2015
Streptococcal Infections Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical trial r...
30 Dec 2015 by Global Data USD $2,125 (normally
USD $2,500)
More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Streptococcal Pneumonia - Pipeline Review, H2 2016 [Published by Global Markets Direct] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...